Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma

Immune checkpoint blockade and MAPK-targeted combined therapy is a promising regimen for advanced melanoma patients. However, the clinical benefit from this combo regimen remains limited, especially in patients who acquired resistance to MAPK-targeted therapy. Here, we systematically characterized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jing, Wu, Xi, Song, Jinen, Zhao, Yujie, Li, Huifang, Luo, Min, Liu, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459091/
https://www.ncbi.nlm.nih.gov/pubmed/36091815
http://dx.doi.org/10.3389/fphar.2022.928226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459091/
https://www.ncbi.nlm.nih.gov/pubmed/36091815
http://dx.doi.org/10.3389/fphar.2022.928226

Ejemplares similares